- Zen Leaf Norristown, located at 436 Egypt Road, is the Company’s second new dispensary to open in the last month in Montgomery County, a suburban Philadelphia county with a robust population of over 856,0001 residents
- The dispensary complements nearby Zen Leaf locations in Abington, Chester, Clifton Heights, Malvern, Sellersville, West Chester, Wynnewood, and northeast Philadelphia on Welsh Rd.
- Verano’s active operations span 13 states, comprised of 138 dispensaries and 14 cultivation and processing facilities with more than 1 million square feet of cultivation capacity
CHICAGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the grand opening of Zen Leaf Norristown, the Company’s 18th affiliated dispensary in Pennsylvania, on Friday, February 16th following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Norristown is located at 436 Egypt Road, and will be open Monday through Friday from 9 a.m. to 8 p.m., Saturday from 10 a.m. to 7 p.m. and Sunday from 10 a.m. to 6 p.m. local time.
The dispensary is located in Montgomery County, the second largest county in the Commonwealth, with a total population of over 856,0001. Situated at the site of a former bank, Zen Leaf Norristown includes a drive-through window for greater accessibility and convenience for online orders, and large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients.
“Commemorating the opening of Zen Leaf Norristown is a significant milestone for Verano and our phenomenal team as we welcome patients to our 18th affiliated dispensary in the Commonwealth,” said George Archos, Verano Founder and Chief Executive Officer. “Opening Zen Leaf Norristown further enhances our footprint in this key market, and we’re excited to invite patients to experience our welcoming patient-centric hospitality and explore our suite of high quality cannabis products. We’re grateful for the opportunity to serve Pennsylvania’s robust medical cannabis community in the greater Philadelphia metropolitan area with the addition of Zen Leaf Norristown.”
Zen Leaf Norristown adds another convenient outlet for Philadelphia area patients, and extends Verano’s footprint in the state as the Company’s 18th affiliated Pennsylvania dispensary. Verano’s operations in the state also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.
About Verano
Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano offers a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf™ and MÜV™ dispensary banners and produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano™, MÜV™, Savvy™, BITS™, Encore™, and Avexia™. Verano’s active operations span 13 U.S. states, comprised of 14 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at www.verano.com.
Contacts:
Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com
Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com
Forward Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission at www.sec.gov. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.
###
